(Reuters) -Indian drugmaker Aurobindo Pharma reported a 3.8% rise in profit on Wednesday, helped by steady domestic demand, especially for its anti-retroviral drugs for HIV infections.

Consolidated net profit in the second quarter rose to 8.48 billion rupees ($96.48 million) from 8.17 billion rupees a year ago.

Revenue rose 8.37% to 82.86 billion rupees.

For further highlights on earnings, click here

KEY CONTEXT

India’s generic drugmakers get a significant portion of their revenue from North America, where fierce competition has led to lower prices, weighing on their margins. The U.S. contributed 43.9% to Aurobindo’s quarterly consolidated revenue, according to the company’s presentation.

U.S. President Donald Trump had levied tariffs on import of branded and patented drugs from Octo

See Full Page